Post Date: October 23, 2019
More than 40 abstracts to be presented to highlight the latest research in eosinophilic disease
Cincinnati Children’s is pleased to be hosting the 5th CURED Research Conference and Patient Education Program, an international meeting focused on the emerging field of eosinophilic gastrointestinal disorders (EGID), including eosinophilic esophagitis (EoE).
The conference, taking place Nov. 7-9, 2019, will address clinical, pathogenic, genetic, dietary and therapeutic features of EGID. The program features renowned international experts speaking over three days, with the first two days focused on EGID research and the third day on patient and family education. Over 40 abstracts have been accepted for poster presentations, with many late-breaking discoveries being presented as oral presentations. The agenda is downloadable online at www.regonline.com/cured2019.
This event is held by the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation in collaboration with the Cincinnati Center for Eosinophilic Disorders and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), which is funded by the National Institutes of Health (NIH).
This is the fifth such meeting and is being attended by nearly 300 individuals from 20 states in the USA, 7 countries and 4 continents. This meeting is expected to be even more successful than past meetings, as eosinophilic disorders have garnered increased understanding and attention.
Click here to learn more about the conference and register for the event.
Eosinophils are a normal cellular component of the blood and also of certain tissues. When the body wants to attack a substance, such as an allergy-triggering food or airborne allergen, eosinophils respond by moving into the area and releasing a variety of toxins. However, when the body produces too many eosinophils, they can cause chronic inflammation resulting in tissue damage. EGIDs occur when eosinophils are found in above-normal amounts in various parts of the gastrointestinal tract. EGID are chronic disorders, affecting at least 1:1000 people. Current treatment options consist of steroids, humanized antibodies, and/or dietary therapy. Recent research suggests that EGID development occurs through a combination of environmental and genetic factors. Despite off-label usage of approved medicines and active drug development, there are currently no approved drugs for EGID, making this conference timely.
CURED is a not-for-profit foundation dedicated to those suffering from EGIDs, including eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic colitis (EC) and other eosinophilic disorders. CURED is committed to raising substantial funding to aid in research, advocating on behalf of EGID patients and their families, and working to educate and increase awareness about this complex group of diseases. It is our heartfelt belief that CURED can make a difference for the individuals and their families who are touched by these diseases.
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.